System for treating aneurysmal disease
First Claim
1. A drug delivery device comprising:
- an implantable intraluminal medical device; and
a combination of at least two agents, in therapeutic dosages, releasably affixed to the implantable intraluminal medical device for the treatment of aneurysmal disease, a first of the at least two agents being released for a first sustained period of time to regulate the elastolytic activity of a matrix metalloproteinase and gelatinase and a second of the at least two agents being released for a second sustained period of time to reduce inflammation.
2 Assignments
0 Petitions
Accused Products
Abstract
Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism'"'"'s reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism'"'"'s reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.
86 Citations
25 Claims
-
1. A drug delivery device comprising:
-
an implantable intraluminal medical device; and
a combination of at least two agents, in therapeutic dosages, releasably affixed to the implantable intraluminal medical device for the treatment of aneurysmal disease, a first of the at least two agents being released for a first sustained period of time to regulate the elastolytic activity of a matrix metalloproteinase and gelatinase and a second of the at least two agents being released for a second sustained period of time to reduce inflammation. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
- 10. A method for the treatment of aneurysmal disease in artery walls comprising the controlled delivery, by release, for a sustained period of time from an implantable medical device, of at least two agents, the first agent regulating the elastolytic activity of a matrix metalloproteinase and gelatinase and the second agent reducing inflammation.
-
15. An aneurysmal repair device comprising:
at least one bypass prosthesis configured to establish a fluid flow path through an aneurysmal section of an artery;
-and at least two agents affixed to at least a portion of the at least one bypass prosthesis, a first of the at least two agents being released for a sustained period of time to regulate the elastolytic activity of a matrix metalloproteinase and gelatinase and a second of the at least two agents being released for a second sustained period of time to reduce inflammation.- View Dependent Claims (16, 17, 18, 19, 20, 21, 22, 23)
-
24. An aneurysmal repair device comprising:
-
at least one-bypass prosthesis configured to establish a fluid flow path through an aneurysmal section of an artery; and
a drug delivery depot operatively associated with the at least one-bypass prosthesis, the drug delivery depot configured to deliver at least two agents, a first of the at least two agents being released for a first sustained period of time to regulate the elastolytic activity of a matrix metalloproteinase and gelatinase and a second of the at least two agents being released for a second sustained period of time to reduce inflammation.
-
-
25. A method for treating aneurysmal disease comprising:
-
positioning at least one-bypass prosthesis within a vessel to establish a fluid flow path through an aneurysmal section of the vessel; and
locally delivering at least two agents to the aneurysmal site, a first of the at least two agents being released for a first sustained period of time to regulate the elastolytic activity of a matrix metalloproteinase and gelatinase and a second of the at least two agents being released for a second sustained period of time to reduce inflammation.
-
Specification
-
- Resources
-
Current AssigneeWyeth (Pfizer Inc.)
-
Original AssigneeWyeth (Pfizer Inc.)
-
InventorsNarayanan, Pallasssana
-
Application NumberUS11/193,177Publication NumberTime in Patent OfficeDaysField of SearchUS Class Current424/426CPC Class CodesA61L 17/005 containing a biologically a...A61L 17/145 CoatingA61L 2300/406 AntibioticsA61L 2300/41 Anti-inflammatory agents, e...A61L 2300/416 Anti-neoplastic or anti-pro...A61L 2300/43 Hormones, e.g. dexamethasoneA61L 27/34 Macromolecular materialsA61L 27/54 Biologically active materia...A61L 31/10 Macromolecular materialsA61L 31/16 Biologically active materia...A61P 9/00 Drugs for disorders of the ...
